ArriVent BioPharma, Inc. AVBP Business Segments — Net Income Loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ArriVent BioPharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about ArriVent BioPharma, Inc.'s business segments — net income loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ArriVent BioPharma, Inc.'s business segments — net income loss?
- ArriVent BioPharma, Inc. (AVBP) reported business segments — net income loss of -$43.32M in Q1 2026.
- How has ArriVent BioPharma, Inc.'s business segments — net income loss changed year-over-year?
- ArriVent BioPharma, Inc.'s business segments — net income loss increased by 32.7% year-over-year, from -$64.39M to -$43.32M.
- What is the long-term trend for ArriVent BioPharma, Inc.'s business segments — net income loss?
- Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s business segments — net income loss has grown at a 54.9% compound annual growth rate (CAGR), from -$69.33M to -$166.31M.
- What does business segments — net income loss mean?
- This metric represents the total profit or loss generated by the business segment after accounting for all revenues and operating expenses. For clinical-stage companies, this typically reflects the net burn rate as the firm invests heavily in drug development without significant commercial revenue. It is the primary indicator of the segment's overall financial health and sustainability.